Gladstone Capital (NASDAQ:GLAD) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.19 by 5.26 percent. This is unchanged from the same period last year.
Freeline Therapeutics Outlines 2022 Corporate Priorities, Guidance
Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease; potential to deliver transformative therapies driven by Freeline’s differentiated platform
Data anticipated
